Clinical Trial determines CNM-Au8 as a Potential Treatment for ALS

ALS, a disease that weakens muscles and affects how the body moves, doesn’t have a cure yet. But scientists are exploring treatments, and one exciting clinical trial looked at something called CNM-Au8 to see if it could help.

What's CNM-Au8? It's like a tiny special medicine made of gold that might protect our nerve cells. Scientists hoped it could help slow down ALS by boosting energy in our cells and reducing stress.

Clinical trial

In the trial, 45 people with ALS took part. They were split into two groups. One group got CNM-Au8 every day for 36 weeks, and the other group received a pretend pill called a placebo. Everyone also took a regular ALS medicine called riluzole.

The main thing scientists wanted to check was how well people's muscles worked using a special test called MUNIX. They also looked at breathing and other things to see if CNM-Au8 made a difference.

Results

At the end of the 36 weeks, the results were interesting. The test for muscle function (MUNIX) and other measurements didn't show a big difference between the group taking CNM-Au8 and the group taking the pretend pill.

But here's the exciting part: when they checked on everyone a year later, they found something surprising. People who took CNM-Au8 had a 60% lower risk of passing away compared to those who had the pretend pill during the trial. This means that the CNM-Au8 might have helped people live longer.

Also, the ones who started with CNM-Au8 and continued it even after the trial seemed to face fewer serious problems related to ALS, like needing help to breathe or eat through tubes.

The best part? The scientists made sure that CNM-Au8 was safe to use. No bad effects were seen, which is great news.

Although the trial didn’t show big changes in muscle tests right away, the other discoveries were exciting. This suggests that CNM-Au8 might be a safe option to help people with ALS live longer and have a better life, especially when combined with regular ALS medicine.

This trial gives us hope. Even though there’s more to understand about how well CNM-Au8 works, it's a step toward finding new ways to fight ALS and help people facing this tough disease.

Conclusion

This clinical trial exploring CNM-Au8 as a potential treatment for ALS offers a glimpse of hope in the fight against this challenging disease. While the 36-week trial didn’t immediately show big changes in muscle function, the longer-term results were incredibly promising.

The discovery that CNM-Au8 might help people live longer and experience a slower progression of ALS is a significant finding. The fact that it was also found to be safe for use is a positive sign for potential future treatments.

This trial isn’t the end of the road but rather a stepping stone toward better understanding how CNM-Au8 could benefit people living with ALS. It highlights the importance of ongoing research and opens doors for further investigation into this gold-based therapy.

__________